Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Merger Approval: Ikena Oncology shareholders approved the merger with Inmagene Biopharmaceuticals, which includes issuing shares to Inmagene's shareholders and financing investors. The combined entity will be renamed ImageneBio, Inc. and will trade on Nasdaq under the ticker symbol (IMA).
Reverse Stock Split: Shareholders also approved a reverse stock split, with Ikena set to implement a 1-for-12 split, reducing outstanding shares from approximately 48.2 million to about 4 million, effective around the end of July before the merger closes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
